Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

Trial Profile

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 22 Oct 2018 Planned End Date changed from 16 Oct 2020 to 2 Mar 2021.
    • 22 Oct 2018 Planned primary completion date changed from 15 Oct 2019 to 1 Mar 2020.
    • 22 Oct 2018 Planned initiation date changed from 20 Nov 2018 to 17 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top